NYSEAMERICAN : CLDI
Calidi Biotherapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.64 USD (Oct 30, 2026, 9:18 AM EDT) · Market cap 2.36M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.54M |
| Enterprise Value | 413,314 |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 3.69M |
| Shares Outstanding | 3.70M |
| Shares Change (YoY) | +536.72% |
| Shares Change (QoQ) | +119.79% |
| Owned by Insiders (%) | 0.52% |
| Owned by Institutions (%) | 0.91% |
| Float | 3.67M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.46 |
| P/TBV Ratio | 0.81 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.68 |
| Quick Ratio | 1.34 |
| Debt / Equity | 0.62 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -69.73 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -672.22% |
| Return on Assets (ROA) | -134.79% |
| Return on Invested Capital (ROIC) | -199.91% |
| Return on Capital Employed (ROCE) | -449.99% |
| Weighted Average Cost of Capital (WACC) | 11.06% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$808,793 |
| Employee Count | 29 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 17,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.33 |
| 52-Week Price Change | -97.11% |
| 50-Day Moving Average | 1.07 |
| 200-Day Moving Average | 4.52 |
| Relative Strength Index (RSI) | 27.92 |
| Average Volume (20 Days) | 49,006 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 164,295 |
| Short Previous Month | 227,775 |
| Short % of Shares Out | 4.45% |
| Short % of Float | 4.48% |
| Short Ratio (days to cover) | 0.81 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -17.85M |
| Pretax Income | -17.49M |
| Net Income | -23.46M |
| EBITDA | -16.14M |
| EBIT | -17.85M |
| Earnings Per Share (EPS) | -$33.30 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 4.07M |
| Total Debt | 1.94M |
| Net Cash | 2.13M |
| Net Cash Per Share | $0.58 |
| Equity (Book Value) | 3.13M |
| Book Value Per Share | 1.50 |
| Working Capital | 2.19M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -17.75M |
| Capital Expenditures | -94,000 |
| Depreciation & Amortization | 1.71M |
| Net Borrowing | -522,000 |
| Free Cash Flow | -17.85M |
| FCF Per Share | -$4.83 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -536.72% |
| Shareholder Yield | -536.72% |
| Earnings Yield | -4,839.97% |
| FCF Yield | -701.92% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jul 31, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:16 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |